Lorenzo Dagna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lorenzo Dagna has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Corrado Campochiaro
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
70 shared publications - Giulio Cavalli
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy
38 shared publications - Giuseppe Alvise Ramirez
Ospedale di San Raffaele Istituto di Ricovero e Cura a Carattere Scientifico
30 shared publications - Giacomo De Luca
Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS Ospedale San Raffaele, Milan, Italy
27 shared publications - Alessandro Tomelleri
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy
23 shared publications Giulio Cavalli
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
20 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8894
JAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology
Clinical development of conventional JAK, selective TYK2, and dual TYK2/JAK1 inhibitors has expanded beyond inflammatory arthritis, but evidence across systemic rheumatic diseases varies substantially and the agents are not pharmacologically interchangeable. We conducted a structured narrative review of PubMed/MEDLINE and ClinicalTrials.gov with an initial search in May 2026 and targeted updates through 9 November 2026, prioritizing randomized trials and interpreting observational studies and case reports as exploratory. Findings were organized by the highest direct clinical evidence and the practical conclusions that evidence can support. Upadacitinib for giant cell arteritis and brepocitinib for adult dermatomyositis now have phase 3 evidence and regulatory approval in the United States; upadacitinib is also approved for giant cell arteritis in the European Union. In the 52-week VALOR trial, brepocitinib 30 mg improved mean Total Improvement Score versus placebo (46.5 vs. 31.2; p < 0.001), while serious infections were more frequent (10% vs. 1%). Evidence in systemic lupus erythematosus remains mixed, and phase 3 programs are ongoing. A randomized baricitinib trial in Sjögren disease has a promising conference-abstract result, but full peer-reviewed data are not yet available. Evidence in polymyalgia rheumatica, systemic sclerosis, other vasculitides, VEXAS, and monogenic inflammatory diseases remains less mature. Clinical use should follow disease-specific evidence, regulatory status, and individualized safety assessment; pathway plausibility alone does not establish efficacy or predict response.
- 13 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8894
Open AccessJAK Inhibitors Beyond Arthritis: Expanding Indications and Mechanisms of JAK Inhibitors in Rheumatology
Clinical development of conventional JAK, selective TYK2, and dual TYK2/JAK1 inhibitors has expanded beyond inflammatory arthritis, but evidence across systemic rheumatic diseases varies substantially and the agents are not pharmacologically interchangeable. We conducted a structured narrative review of PubMed/MEDLINE and ClinicalTrials.gov with an initial search in May 2026 and targeted updates through 9 November 2026, prioritizing randomized trials and interpreting observational studies and case reports as exploratory. Findings were organized by the highest direct clinical evidence and the practical conclusions that evidence can support. Upadacitinib for giant cell arteritis and brepocitinib for adult dermatomyositis now have phase 3 evidence and regulatory approval in the United States; upadacitinib is also approved for giant cell arteritis in the European Union. In the 52-week VALOR trial, brepocitinib 30 mg improved mean Total Improvement Score versus placebo (46.5 vs. 31.2; p < 0.001), while serious infections were more frequent (10% vs. 1%). Evidence in systemic lupus erythematosus remains mixed, and phase 3 programs are ongoing. A randomized baricitinib trial in Sjögren disease has a promising conference-abstract result, but full peer-reviewed data are not yet available. Evidence in polymyalgia rheumatica, systemic sclerosis, other vasculitides, VEXAS, and monogenic inflammatory diseases remains less mature. Clinical use should follow disease-specific evidence, regulatory status, and individualized safety assessment; pathway plausibility alone does not establish efficacy or predict response.
- Open Access
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Early Introduction and Prolonged Full‐Dose Anakinra Reduce Recurrence Risk After Discontinuation in Recurrent Pericarditis: An International Multicenter Cohort
Background: Anakinra is effective in recurrent pericarditis, yet optimal treatment duration and strategies for safe drug discontinuation remain uncertain. Identifying predictors of sustained remission after discontinuation is important for clinical management. Methods: We retrospectively analyzed 185 consecutive adult patients with corticosteroid‐dependent and colchicine‐resistant refractory recurrent pericarditis across 16 international referral centers, who permanently discontinued therapy after clinical remission. The primary end point was pericarditis recurrence after drug discontinuation. Univariate and multivariable Cox proportional hazards regression and Kaplan‐Meier analyses were performed to identify demographic, clinical, and therapeutic predictors of postdiscontinuation relapse. Results: Among 185 patients who discontinued anakinra (58.4% women, mean age 50.4±17.8 years, 77% idiopathic cause), treatment was initiated a median of 10 months (interquartile range [IQR], 4.0–19.5) after the first episode and continued at 100 mg/d for a median of 6 months (IQR, 4–12). Over a median follow‐up of 7.2 months (IQR, 1.5–23.3) after discontinuation, 68 patients (36.8%) experienced recurrence, with a median time to recurrence of 2.1 months (IQR, 0.7–8.5). Initiation within 12 months from the first pericarditis episode and maintenance of full‐dose therapy (100 mg/d) for ≥6 months were independently associated with lower recurrence risk (hazard ratio [HR], 0.33 [95% CI, 0.18–0.66]; P =0.001 and HR, 0.48 [95% CI, 0.23–0.86]; P =0.017; respectively). Conclusions: Early initiation of anakinra and maintenance of full‐dose therapy for at least 6 months are associated with a significantly lower risk of relapse after discontinuation and may inform treatment duration and discontinuation strategies in recurrent pericarditis.
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Open AccessEarly Introduction and Prolonged Full‐Dose Anakinra Reduce Recurrence Risk After Discontinuation in Recurrent Pericarditis: An International Multicenter Cohort
Background: Anakinra is effective in recurrent pericarditis, yet optimal treatment duration and strategies for safe drug discontinuation remain uncertain. Identifying predictors of sustained remission after discontinuation is important for clinical management. Methods: We retrospectively analyzed 185 consecutive adult patients with corticosteroid‐dependent and colchicine‐resistant refractory recurrent pericarditis across 16 international referral centers, who permanently discontinued therapy after clinical remission. The primary end point was pericarditis recurrence after drug discontinuation. Univariate and multivariable Cox proportional hazards regression and Kaplan‐Meier analyses were performed to identify demographic, clinical, and therapeutic predictors of postdiscontinuation relapse. Results: Among 185 patients who discontinued anakinra (58.4% women, mean age 50.4±17.8 years, 77% idiopathic cause), treatment was initiated a median of 10 months (interquartile range [IQR], 4.0–19.5) after the first episode and continued at 100 mg/d for a median of 6 months (IQR, 4–12). Over a median follow‐up of 7.2 months (IQR, 1.5–23.3) after discontinuation, 68 patients (36.8%) experienced recurrence, with a median time to recurrence of 2.1 months (IQR, 0.7–8.5). Initiation within 12 months from the first pericarditis episode and maintenance of full‐dose therapy (100 mg/d) for ≥6 months were independently associated with lower recurrence risk (hazard ratio [HR], 0.33 [95% CI, 0.18–0.66]; P =0.001 and HR, 0.48 [95% CI, 0.23–0.86]; P =0.017; respectively). Conclusions: Early initiation of anakinra and maintenance of full‐dose therapy for at least 6 months are associated with a significantly lower risk of relapse after discontinuation and may inform treatment duration and discontinuation strategies in recurrent pericarditis.
- Open Access
- 6 October 2026
- Published by Wiley in HemaSphere
- Vol. 10 (10) , e70499
MEK inhibition achieves robust and durable responses in Erdheim–Chester disease
Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by heterogeneous clinical manifestations and limited evidence to guide targeted therapy. While MEK inhibitors (MEKi) are increasingly used, data on their real‐world efficacy, durability, and safety remain incomplete. We analyzed outcomes of patients with ECD treated with MEKi monotherapy across eight countries and assessed the dynamics and predictors of response, treatment retention, and the safety profile of MEKi. We included 170 patients and were able to evaluate response in 159 (94%) of them. Objective responses were observed in 112 patients (70%), disease stabilization in 35 (22%), and disease progression in 12 (8%). Response rates were independent of treatment lines and underlying molecular alterations. The median time to best response was 14 months, with an estimated 2‐year probability of response of 61% (95% CI 51%–67%). In multivariable analysis, dyslipidemia (odds ratio [OR] 0.359, 95% CI 0.171–0.745) and neurodegeneration (OR 0.354, 95% CI 0.144–0.864) were associated with a lower probability of response to MEKi, while cutaneous and gastrointestinal involvement with a higher probability. After a median follow‐up of 27 months (interquartile range [IQR] 12–57), the treatment retention rate was 76%, with most discontinuations attributable to toxicity. Adverse events were reported in 106 patients (62%) and were severe in 39 patients (23%). The estimated 2‐year event‐free survival was 65% (95% CI 57%–72%), and the estimated 2‐year overall survival was 80% (95% CI 72%–86%). MEKi monotherapy provides robust and durable clinical efficacy in patients with ECD, with high response rates and favorable long‐term outcomes, despite a substantial burden of toxicity.
- 6 October 2026
- Published by Wiley in HemaSphere
- Vol. 10 (10) , e70499
Open AccessMEK inhibition achieves robust and durable responses in Erdheim–Chester disease
Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by heterogeneous clinical manifestations and limited evidence to guide targeted therapy. While MEK inhibitors (MEKi) are increasingly used, data on their real‐world efficacy, durability, and safety remain incomplete. We analyzed outcomes of patients with ECD treated with MEKi monotherapy across eight countries and assessed the dynamics and predictors of response, treatment retention, and the safety profile of MEKi. We included 170 patients and were able to evaluate response in 159 (94%) of them. Objective responses were observed in 112 patients (70%), disease stabilization in 35 (22%), and disease progression in 12 (8%). Response rates were independent of treatment lines and underlying molecular alterations. The median time to best response was 14 months, with an estimated 2‐year probability of response of 61% (95% CI 51%–67%). In multivariable analysis, dyslipidemia (odds ratio [OR] 0.359, 95% CI 0.171–0.745) and neurodegeneration (OR 0.354, 95% CI 0.144–0.864) were associated with a lower probability of response to MEKi, while cutaneous and gastrointestinal involvement with a higher probability. After a median follow‐up of 27 months (interquartile range [IQR] 12–57), the treatment retention rate was 76%, with most discontinuations attributable to toxicity. Adverse events were reported in 106 patients (62%) and were severe in 39 patients (23%). The estimated 2‐year event‐free survival was 65% (95% CI 57%–72%), and the estimated 2‐year overall survival was 80% (95% CI 72%–86%). MEKi monotherapy provides robust and durable clinical efficacy in patients with ECD, with high response rates and favorable long‐term outcomes, despite a substantial burden of toxicity.
- 20 July 2026
- Published by Elsevier in European Journal of Internal Medicine
The challenge of innovation in lupus between abstraction and reality
- 20 July 2026
- Published by Elsevier in European Journal of Internal Medicine
The challenge of innovation in lupus between abstraction and reality
- Open Access
Distinctive Inflammatory Traits of Parvovirus B19 Infection Associated with Persisting Autoimmunity
Background: Adult parvovirus B19 (B19V) infection occurs with cyclic outbreaks and can be associated with inflammatory manifestations mimicking or heralding the onset of systemic autoimmune diseases. Little is known about clinical traits distinguishing patients with transient vs. persisting manifestations. Methods: Leveraging data from the 2024 B19V infection outbreak, we set up a retrospective, multicentre, observational study investigating the epidemiology and clinical phenotypes of patients with B19V infection presenting to tertiary care for immune-mediated manifestations, including patients with pre-existing autoimmunity. Results: A total of 39 B19V infections were identified, yielding an annual incidence of 1.78 cases/1000 patients. Autoimmune rheumatic diseases were pre-existing in 7/39 and newly diagnosed in 5/39. One patient was hospitalised. Arthritis was more frequent in new-onset (89%) than in pre-existing (14%; p = 0.010) or no autoimmunity (19%; p < 0.001). Anaemia was not found in patients with pre-existing autoimmunity in contrast to those with new autoimmune disease diagnoses (40%; p = 0.039) or transient manifestations (52%; p = 0.013). Skin manifestations were numerically less frequent in this latter group (56%) than in patients with pre-existing (100%) or newly onset autoimmunity (80%). Autoantibodies were detected in 44% of cases and were more frequent in patients with constitutional symptoms but were not confirmed in the long term in most cases. Glucocorticoids were more frequently employed in patients with new-onset rather than pre-existing autoimmune diseases (p = 0.006) or without chronic autoimmunity (p = 0.027). Conclusion: B19V-associated new-onset autoimmunity may occur in one in six cases observed in tertiary immunology care, show distinct clinical features, and require significant immunosuppression.
Open AccessDistinctive Inflammatory Traits of Parvovirus B19 Infection Associated with Persisting Autoimmunity
Background: Adult parvovirus B19 (B19V) infection occurs with cyclic outbreaks and can be associated with inflammatory manifestations mimicking or heralding the onset of systemic autoimmune diseases. Little is known about clinical traits distinguishing patients with transient vs. persisting manifestations. Methods: Leveraging data from the 2024 B19V infection outbreak, we set up a retrospective, multicentre, observational study investigating the epidemiology and clinical phenotypes of patients with B19V infection presenting to tertiary care for immune-mediated manifestations, including patients with pre-existing autoimmunity. Results: A total of 39 B19V infections were identified, yielding an annual incidence of 1.78 cases/1000 patients. Autoimmune rheumatic diseases were pre-existing in 7/39 and newly diagnosed in 5/39. One patient was hospitalised. Arthritis was more frequent in new-onset (89%) than in pre-existing (14%; p = 0.010) or no autoimmunity (19%; p < 0.001). Anaemia was not found in patients with pre-existing autoimmunity in contrast to those with new autoimmune disease diagnoses (40%; p = 0.039) or transient manifestations (52%; p = 0.013). Skin manifestations were numerically less frequent in this latter group (56%) than in patients with pre-existing (100%) or newly onset autoimmunity (80%). Autoantibodies were detected in 44% of cases and were more frequent in patients with constitutional symptoms but were not confirmed in the long term in most cases. Glucocorticoids were more frequently employed in patients with new-onset rather than pre-existing autoimmune diseases (p = 0.006) or without chronic autoimmunity (p = 0.027). Conclusion: B19V-associated new-onset autoimmunity may occur in one in six cases observed in tertiary immunology care, show distinct clinical features, and require significant immunosuppression.
- Open Access
- 9 July 2026
- Published by Elsevier in Molecular Therapy Advances
- Vol. 34 (3)
Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient derived CAR-Tregs
- 9 July 2026
- Published by Elsevier in Molecular Therapy Advances
- Vol. 34 (3)
Open AccessDouble activation and low IL-2 manufacturing protocol increase expansion of healthy and patient derived CAR-Tregs
- 27 May 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 150, 106950
Beyond categorical exclusion: Reclaiming clinical judgment in the use of JAK inhibitors for rheumatoid arthritis
- 27 May 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 150, 106950
Beyond categorical exclusion: Reclaiming clinical judgment in the use of JAK inhibitors for rheumatoid arthritis
- 19 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 89
Targeting type I interferon in lupus panniculitis: a case-based systematic literature review
Lupus panniculitis (LEP) is a rare form of cutaneous lupus (CLE) characterised by progressive, often disfiguring course and poor response to treatment. Type I interferon inhibition through anifrolumab (ANF) is effective in CLE but limited data are available for its use in LEP. To address this issue, we screened patients with CLE and/or systemic lupus erythematosus (SLE) for biopsy-proven diagnoses of LEP and treatment with ANF. Besides demographics, general clinical features, concomitant treatments before and after ANF and safety signals, we measured disease activity and damage with the SLE disease activity index 2000 (SLEDAI-2 K), the CLE Disease Area and Severity Index activity (CLASI-A) and damage scores and the SLE International collaborating clinics/American College of Rheumatology damage index. The same data were retrieved, when available, from existing cases extracted from systematic literature review. Sixteen cases were identified, including 3/421 newly described patients, with two receiving ANF as first-line immunosuppressant and one as an early treatment devoid of oral corticosteroids. All patients had a good response to treatment and most of them could taper or discontinue corticosteroids. CLASI-A scores were markedly reduced after ANF treatment [11.5 (7–29)] to 0 (0–2); p = 0.005]. The time to response was within five months in most cases. No significant adverse events were reported. Taken together, our data suggest that ANF might be effective in LEP and used as a first-line treatment to prevent LEP-related damage accrual.
- 19 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 89
Targeting type I interferon in lupus panniculitis: a case-based systematic literature review
Lupus panniculitis (LEP) is a rare form of cutaneous lupus (CLE) characterised by progressive, often disfiguring course and poor response to treatment. Type I interferon inhibition through anifrolumab (ANF) is effective in CLE but limited data are available for its use in LEP. To address this issue, we screened patients with CLE and/or systemic lupus erythematosus (SLE) for biopsy-proven diagnoses of LEP and treatment with ANF. Besides demographics, general clinical features, concomitant treatments before and after ANF and safety signals, we measured disease activity and damage with the SLE disease activity index 2000 (SLEDAI-2 K), the CLE Disease Area and Severity Index activity (CLASI-A) and damage scores and the SLE International collaborating clinics/American College of Rheumatology damage index. The same data were retrieved, when available, from existing cases extracted from systematic literature review. Sixteen cases were identified, including 3/421 newly described patients, with two receiving ANF as first-line immunosuppressant and one as an early treatment devoid of oral corticosteroids. All patients had a good response to treatment and most of them could taper or discontinue corticosteroids. CLASI-A scores were markedly reduced after ANF treatment [11.5 (7–29)] to 0 (0–2); p = 0.005]. The time to response was within five months in most cases. No significant adverse events were reported. Taken together, our data suggest that ANF might be effective in LEP and used as a first-line treatment to prevent LEP-related damage accrual.
- Open Access
- 12 April 2026
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 13 (3) , 767-784
Achievement and Maintenance of Remission with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in Italy: 1-Year Data from UPHOLD, a Prospective Real-World Observational Study
Introduction Upadacitinib (UPA) is approved for moderate-to-severe rheumatoid arthritis (RA) based on SELECT trials, but data on real-world effectiveness are limited. UPHOLD is a multicountry study of patients with RA receiving UPA 15 mg. Methods The present interim analysis was based on the Italian cohort performed across 28 centers. Co-primary endpoints were (i) the proportion of patients receiving UPA who achieved DAS28(CRP) remission (< 2.6) at 6 months and (ii) the proportion of patients achieving DAS28(CRP) remission at 6 months who continued to receive UPA and maintained remission (or had no more than a 0.6-point increase in DAS28[CRP]) at 12 months, analyzed by modified non-responder imputation (mNRI) and as observed (AO). Modified full analysis sets (mFAS1 and mFAS2) included patients completing 6 and 12 months, respectively. Safety analysis included reporting of adverse events and treatment-emergent adverse events (TEAEs), as exposure-adjusted event rates (EAERs; events per 100 patient-years [E/100PY]). Results Among 270 patients, 74 (27.4%) discontinued by 12 months because of lack of efficacy (13.7%) or adverse events (8.1%). In mFAS1 (N = 168), 50.6% (mNRI) and 62% (AO) achieved DAS28(CRP) remission at 6 months. In mFAS2 (N = 55), 80% (mNRI) and 91.7% (AO) maintained DAS28(CRP) remission at 12 months. CDAI and SDAI remission rates at 12 months were 31.3%. Patients on UPA monotherapy at 12 months showed remission rates of 49.5% (DAS28[CRP]), 27.2% (CDAI), and 27.4% (SDAI). Significant improvements in patient-reported pain and physical function were also observed. A total of 278 TEAEs were reported (80.8 E/100PY), including herpes zoster, liver disorders, and serious infections with EAERs of 2.0, 1.5, and 1.2 E/100PY, respectively. Conclusion UPA 15 mg was observed to effectively treat moderate-to-severe RA in the real-world setting, with ≥ 80% maintaining DAS28(CRP) remission at 12 months, showing a favorable benefit–risk profile. Trial Registration ClinicalTrials.gov identifier, NCT04497597.
- 12 April 2026
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 13 (3) , 767-784
Open AccessAchievement and Maintenance of Remission with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in Italy: 1-Year Data from UPHOLD, a Prospective Real-World Observational Study
Introduction Upadacitinib (UPA) is approved for moderate-to-severe rheumatoid arthritis (RA) based on SELECT trials, but data on real-world effectiveness are limited. UPHOLD is a multicountry study of patients with RA receiving UPA 15 mg. Methods The present interim analysis was based on the Italian cohort performed across 28 centers. Co-primary endpoints were (i) the proportion of patients receiving UPA who achieved DAS28(CRP) remission (< 2.6) at 6 months and (ii) the proportion of patients achieving DAS28(CRP) remission at 6 months who continued to receive UPA and maintained remission (or had no more than a 0.6-point increase in DAS28[CRP]) at 12 months, analyzed by modified non-responder imputation (mNRI) and as observed (AO). Modified full analysis sets (mFAS1 and mFAS2) included patients completing 6 and 12 months, respectively. Safety analysis included reporting of adverse events and treatment-emergent adverse events (TEAEs), as exposure-adjusted event rates (EAERs; events per 100 patient-years [E/100PY]). Results Among 270 patients, 74 (27.4%) discontinued by 12 months because of lack of efficacy (13.7%) or adverse events (8.1%). In mFAS1 (N = 168), 50.6% (mNRI) and 62% (AO) achieved DAS28(CRP) remission at 6 months. In mFAS2 (N = 55), 80% (mNRI) and 91.7% (AO) maintained DAS28(CRP) remission at 12 months. CDAI and SDAI remission rates at 12 months were 31.3%. Patients on UPA monotherapy at 12 months showed remission rates of 49.5% (DAS28[CRP]), 27.2% (CDAI), and 27.4% (SDAI). Significant improvements in patient-reported pain and physical function were also observed. A total of 278 TEAEs were reported (80.8 E/100PY), including herpes zoster, liver disorders, and serious infections with EAERs of 2.0, 1.5, and 1.2 E/100PY, respectively. Conclusion UPA 15 mg was observed to effectively treat moderate-to-severe RA in the real-world setting, with ≥ 80% maintaining DAS28(CRP) remission at 12 months, showing a favorable benefit–risk profile. Trial Registration ClinicalTrials.gov identifier, NCT04497597.
- Open Access
Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study
Background: Tocilizumab (TCZ) has shown beneficial effects on interstitial lung disease (ILD) in systemic sclerosis (SSc). We aimed to assess the real-life safety and effectiveness of TCZ on several SSc-related domains using data from a French-Italian multicentre cohort. Methods: We conducted a retrospective analysis of patients with SSc treated with TCZ across 15 referral centres. The following clinical data were collected at 12 months before TCZ initiation, at baseline and at 12 and 24 months of treatment: modified Rodnan skin score (mRSS), pulmonary function tests, Disease Activity Score in 28 joints using C reactive protein, digital ulcers and cardiac biomarkers. ILD progression was defined as a decline ≥5 in %predicted forced vital capacity (%pFVC) over 12±3 months. Results: 197 patients were included (88% female; median age 57 years; median disease duration 9 years); 67% were antitopoisomerase I positive. TCZ monotherapy was used in 29% of cases, methotrexate was the most frequent combined treatment (35%). In SSc-associated ILD, %pFVC declined significantly from −12 months to baseline (81% to 77%; p=0.003). On TCZ introduction, %pFVC stabilised and the proportion of progressors declined from 43% to 24% (p=0.015). Among diffuse cutaneous patients, mRSS decreased significantly at 12 and 24 months. Digital ulcers, arthritis activity and cardiac biomarkers also improved. Infections were the most frequent adverse events (22.8%). TCZ was discontinued in 32% of patients, mainly for inefficacy. Pulmonary arterial hypertension and older age predicted TCZ failure, whereas elevated CRP predicted better response. Conclusions: In this large real-life cohort, TCZ was safe and associated with consistent benefits across different domains, supporting its role as a potential disease-modifying treatment in selected patients with SSc.
Open AccessSafety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study
Background: Tocilizumab (TCZ) has shown beneficial effects on interstitial lung disease (ILD) in systemic sclerosis (SSc). We aimed to assess the real-life safety and effectiveness of TCZ on several SSc-related domains using data from a French-Italian multicentre cohort. Methods: We conducted a retrospective analysis of patients with SSc treated with TCZ across 15 referral centres. The following clinical data were collected at 12 months before TCZ initiation, at baseline and at 12 and 24 months of treatment: modified Rodnan skin score (mRSS), pulmonary function tests, Disease Activity Score in 28 joints using C reactive protein, digital ulcers and cardiac biomarkers. ILD progression was defined as a decline ≥5 in %predicted forced vital capacity (%pFVC) over 12±3 months. Results: 197 patients were included (88% female; median age 57 years; median disease duration 9 years); 67% were antitopoisomerase I positive. TCZ monotherapy was used in 29% of cases, methotrexate was the most frequent combined treatment (35%). In SSc-associated ILD, %pFVC declined significantly from −12 months to baseline (81% to 77%; p=0.003). On TCZ introduction, %pFVC stabilised and the proportion of progressors declined from 43% to 24% (p=0.015). Among diffuse cutaneous patients, mRSS decreased significantly at 12 and 24 months. Digital ulcers, arthritis activity and cardiac biomarkers also improved. Infections were the most frequent adverse events (22.8%). TCZ was discontinued in 32% of patients, mainly for inefficacy. Pulmonary arterial hypertension and older age predicted TCZ failure, whereas elevated CRP predicted better response. Conclusions: In this large real-life cohort, TCZ was safe and associated with consistent benefits across different domains, supporting its role as a potential disease-modifying treatment in selected patients with SSc.